For the first time ever, scientists have come up with results from clinical experiments suggesting that there are drugs for prostate cancer patients whose conditions are aggressive enough to defy standard hormonal therapy. The drugs are capable of delaying the spread of cancer to the bones, lymph and other organs for a period of two years.
The two drugs are apalutamide and enzalutamide. The New England Journal of Medicine has published the apalutamide drug while enzalutamide is already under use by cancer patients awaiting its publication.
Generally, prostate cancer is very common in men all over the world. It is reported by the American Cancer Society that the disease claims the lives of 29,430 patients. The World Health Organization confirms that about 307,000 deaths are directly related to cancer. Most of the deaths occur given failures of cancer treatments to suppress the testosterone when patients receive cancer treatment. It is estimated that about 200,000 cancer patients who have undergone various prostate cancer treatments show rapid increase in their prostate-specific antigen (PSA), according to the study on apalutamide done by Dr. Eric Small and Dr.Mathew Smith at the University of California.
In this study on efficiency of apalutamide, it is discovered that the drug helps reduce the spread of cancer at a slower rate compared to other drugs such as placebo. The cancer spreads in only 16.2 months in men receiving the placebo drugs while it takes only 40.5 months for men receiving the apalutamide drugs. The androgen receptor inhibitors can reduce the spread of prostate cancer by decreasing the production of testosterone.
However, the ability of the drugs to reduce the spread of prostate cancer depends on the patients’ immunity. This means that there is need to monitor the progress made per patient in order to confirm the efficiency of these drugs.